



Toxicological Profile for Perfluoroalkyls

Draft for Public Comment

June 2018



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch

Regular Mailing Address:
1600 Clifton Road, N.E.
Mail Stop F-57
Atlanta, Georgia 30329-4027

Physical Mailing Address:
4770 Buford Highway
Building 102, 1st floor, MS F-57
Chamblee, Georgia 30341

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
June 2018	Draft for public comment toxicological profile released
August 2015	Draft for public comment toxicological profile released
May 2009	Draft for public comment toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Selene Chou, Ph.D. (Lead)
Dennis Jones, DVM, Ph.D.
Hana R. Pohl, M.D., Ph.D.
Patricia Ruiz, Ph.D.
Franco Scinicariello, M.D., M.P.H.
Melanie Buser, M.P.H.

Lisa Ingerman, Ph.D., DABT
Lynn Barber, M.S.
Heather Carlson-Lynch, M.S., DABT
Mario Citra, Ph.D.
Gary L. Diamond, Ph.D.
Julie Klotzbach, Ph.D.
Fernando T. Lladós, Ph.D.
Daniel J. Plewak, B.S.

ATSDR, Division of Toxicology and Human Health
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; EPA; NCEH, Division of Laboratory Science.

PEER REVIEWERS

1. David A. Savitz, Ph.D., Professor of Epidemiology, Professor of Obstetrics and Gynecology, Brown University, Providence, Rhode Island
2. Deborah A. Cory-Slechta, Ph.D., Professor of Environmental Medicine, Pediatrics and Public Health Sciences, Acting Chair, Department of Environmental Medicine, PI, NIEHS Center of Excellence, Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York
3. Jamie DeWitt, Ph.D., Associate Professor, Department of Pharmacology & Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina
4. Edward Emmett, M.D., Professor, Center of Excellence in Environmental Toxicology, University of Pennsylvania, Philadelphia, Pennsylvania

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

FOREWORD	ii
VERSION HISTORY	iv
CONTRIBUTORS & REVIEWERS	v
CONTENTS.....	vi
LIST OF FIGURES	ix
LIST OF TABLES	xii
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	4
1.3 MINIMAL RISK LEVELS (MRLs)	15
CHAPTER 2. HEALTH EFFECTS.....	21
2.1 INTRODUCTION.....	21
2.2 DEATH	106
2.3 BODY WEIGHT	109
2.4 RESPIRATORY	121
2.5 CARDIOVASCULAR	123
2.6 GASTROINTESTINAL.....	135
2.7 HEMATOLOGICAL	137
2.8 MUSCULOSKELETAL	141
2.9 HEPATIC	146
2.10 RENAL.....	202
2.11 DERMAL	219
2.12 OCULAR.....	220
2.13 ENDOCRINE.....	221
2.14 IMMUNOLOGICAL	244
2.15 NEUROLOGICAL.....	293
2.16 REPRODUCTIVE.....	300
2.17 DEVELOPMENTAL	340
2.18 OTHER NONCANCER	406
2.19 CANCER.....	418
2.20 MECHANISM OF TOXICITY	433
2.20.1 Cellular Mechanisms of Toxicity	434
2.20.2 Hepatic Toxicity Mechanisms.....	441
2.20.3 Developmental Toxicity Mechanisms.....	443
2.20.4 Immunotoxicity Mechanisms	444
2.20.5 Endocrine Mechanisms	445
2.20.6 Cancer Mechanisms	446
2.21 GENOTOXICITY	447
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	450
3.1 TOXICOKINETICS.....	450
3.1.1 Absorption.....	451
3.1.2 Distribution	455
3.1.3 Metabolism.....	469
3.1.4 Excretion	469

3.1.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	493
3.1.5.1	Loccisano et al. (2012a, 2012b) Rat Models	494
3.1.5.2	Loccisano et al. (2011, 2013) Monkey and Human Models	500
3.1.5.3	Rodriguez et al. (2009) Mouse Model	504
3.1.5.4	Wambaugh et al. 2013 (Andersen et al. 2006) Model	506
3.1.5.5	Harris and Barton (2008) Rat Model	509
3.1.5.6	Worley and Fisher (2015a, 2015b) Rat Model	512
3.1.5.7	Worley et al. (2017b) Human Model	513
3.1.5.8	Fàbrega et al. (2014, 2016) Human Model	513
3.1.6	Animal-to-Human Extrapolations	514
3.2	CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE...	515
3.3	BIOMARKERS OF EXPOSURE AND EFFECT	518
3.3.1	Biomarkers of Exposure.....	519
3.3.2	Biomarkers of Effect.....	520
3.4	INTERACTIONS WITH OTHER CHEMICALS	520
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		521
4.1	CHEMICAL IDENTITY.....	521
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	521
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		533
5.1	OVERVIEW.....	533
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	537
5.2.1	Production	537
5.2.2	Import/Export.....	545
5.2.3	Use	545
5.2.4	Disposal.....	546
5.3	RELEASES TO THE ENVIRONMENT	546
5.3.1	Air	551
5.3.2	Water.....	552
5.3.3	Soil	554
5.4	ENVIRONMENTAL FATE	555
5.4.1	Transport and Partitioning.....	555
5.4.2	Transformation and Degradation	559
5.5	LEVELS IN THE ENVIRONMENT	561
5.5.1	Air	564
5.5.2	Water.....	571
5.5.3	Sediment and Soil	582
5.5.4	Other Media	587
5.6	GENERAL POPULATION EXPOSURE.....	596
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	623
CHAPTER 6. ADEQUACY OF THE DATABASE.....		628
6.1	Existing Information on Health Effects.....	628
6.2	Identification of Data Needs.....	632
6.3	Ongoing Studies	642
CHAPTER 7. REGULATIONS AND GUIDELINES		644
CHAPTER 8. REFERENCES		647

APPENDICES

APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS.....	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR PERFLUOROALKYLS	B-1
APPENDIX C. USER'S GUIDE	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E. GLOSSARY	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to PFOA.....	7
1-2. Health Effects Found in Animals Following Oral Exposure to PFOS	8
1-3. Health Effects Found in Animals Following Oral Exposure to Other Perfluoroalkyls	9
1-4. Summary of Sensitive Targets of PFOA – Oral	17
1-5. Summary of Sensitive Targets of PFOS – Oral.....	18
2-1. Overview of the Number of Studies Examining PFOA Health Effects.....	27
2-2. Overview of the Number of Studies Examining PFOS Health Effects	28
2-3. Overview of the Number of Studies Examining Other Perfluoroalkyls Health Effects	29
2-4. Levels of Significant Exposure to PFOA – Inhalation	32
2-5. Levels of Significant Exposure to Other Perfluoroalkyls – Inhalation.....	34
2-6. Levels of Significant Exposure to PFOA – Oral	58
2-7. Levels of Significant Exposure to PFOS – Oral.....	81
2-8. Levels of Significant Exposure to Other Perfluoroalkyls – Oral.....	99
2-9. Serum Total Cholesterol Levels Relative to Serum PFOA Levels.....	173
2-10. Risk of Abnormal Cholesterol Levels Relative to PFOA Levels (Presented as Adjusted Ratios)	174
2-11. Serum LDL Cholesterol Levels Relative to Serum PFOA Levels	175
2-12. Risk of Abnormal LDL Cholesterol Levels Relative to PFOA Levels (Presented as Adjusted Ratios).....	176
2-13. Serum Total Cholesterol Levels Relative to Serum PFOS Levels	189
2-14. Risk of Abnormal Cholesterol Levels Relative to PFOS Levels (Presented as Adjusted Ratios)	190
2-15. Serum LDL Cholesterol Levels Relative to Serum PFOS Levels	191
2-16. Risk of Abnormal LDL Cholesterol Levels Relative to PFOS Levels (Presented as Adjusted Ratios).....	192
2-17. Risk of Hyperuricemia Relative to PFOA Levels (Presented as Adjusted Odds Ratios).....	213
2-18. Risk of Hyperuricemia Relative to PFOS Levels (Presented as Adjusted Odds Ratios).....	215

2-19. Antibody Responses Relative to Serum PFOA Levels in Epidemiology Studies	270
2-20. Risk of Asthma Diagnosis Relative to PFOA Levels (Presented as Adjusted Odds Ratios).....	272
2-21. Antibody Responses Relative to Serum PFOS Levels in Epidemiology Studies	278
2-22. Risk of Asthma Diagnosis Relative to PFOS Levels (Presented as Adjusted Odds Ratios)	280
2-23. Antibody Responses Relative to Serum PFHxS Levels in Epidemiology Studies	283
2-24. Risk of Asthma Diagnosis Relative to PFHxS Levels (Presented as Adjusted Odds Ratios)	285
2-25. Antibody Responses Relative to Serum PFNA Levels in Epidemiology Studies	287
2-26. Risk of Asthma Diagnosis Relative to PFNA Levels (Presented as Adjusted Odds Ratios).....	288
2-27. Antibody Responses Relative to Serum PFDeA Levels in Epidemiology Studies	290
2-28. Risk of Asthma Diagnosis Relative to PFDeA Levels (Presented as Adjusted Odds Ratios).....	292
2-29. Fecundability Relative to PFOA Levels (Presented as Adjusted Fecundability Ratios)	326
2-30. Infertility Relative to PFOA Levels (Presented as Adjusted Odds Ratios)	327
2-31. Fecundability Relative to PFOS Levels (Presented as Adjusted Fecundability Ratios).....	333
2-32. Infertility Relative to PFOS Levels (Presented as Adjusted Odds Ratios).....	334
2-33. Risk of Low Birth Weight Infant Relative to PFOA Levels (Presented as Adjusted Odds Ratios)	379
2-34. Risk of Small For Gestational Age Infant Relative to PFOA Levels (Presented as Adjusted Odds Ratios)	380
2-35. Risk of Low Birth Weight Infant Relative to PFOS Levels (Presented as Adjusted Odds Ratios)	391
2-36. Risk of Small for Gestational Age Infant Relative to PFOS Levels (Presented as Adjusted Odds Ratios)	392
2-37. Diabetes Risk Relative to Serum PFOA Levels (Presented as Adjusted Ratios)	415
2-38. Diabetes Risk Relative to Serum PFOS Levels (Presented as Adjusted Odds Ratios).....	417
3-1. Tissue Concentrations of ¹⁴ C in Male and Female Rats Following a Single Gavage Dose of [¹⁴ C]PFOA at 1, 5, or 25 mg/kg.....	458
3-2. Tissue Concentrations of ¹⁴ C in Male (Upper Panel) and Female (Lower Panel) Rats Following Oral Doses of PFOA for 28 Days at Doses of 3, 10, or 30 mg/kg/day	459

3-3. Structure of PBPK Model of PFOA and PFOS in the Rat.....	495
3-4. PBPK Model Structure for Simulating PFOA and PFOS Exposure During Gestation in the Rat (Dam, Left; Fetus, Right).....	496
3-5. PBPK Model Structure for Simulating PFOA/PFOS Exposure During Lactation in the Rat (Dam, Left; Pup, Right).....	497
3-6. Structure of PBPK Model for PFOA and PFOS in Monkeys and Humans.....	501
3-7. Renal Resorption Pharmacokinetic Model of Gestation and Lactation used in the Analysis of CD-1 Mice	505
3-8. Andersen et al. (2006) Pharmacokinetic Model with Oral Absorption	507
3-9. Conceptual Representation of a Physiologically Based Pharmacokinetic Model for PFOS Exposure in Rats.....	510
5-1. Number of NPL Sites with Perfluoroalkyls Contamination	533
5-2. Timeline of Important Events in the History of Polyfluorinated Compounds.....	539
6-1. Summary of Existing Health Effects Studies on PFOA By Route and Endpoint.....	629
6-2. Summary of Existing Health Effects Studies on PFOS By Route and Endpoint	630
6-3. Summary of Existing Health Effects Studies on Other Perfluoroalkyls By Route and Endpoint	631

LIST OF TABLES

1-1. Summary of Estimated Elimination Half-lives for Select Perfluoroalkyls.....	4
1-2. Overview of Provisional Minimal Risk Levels Derived for Perfluoroalkyl Compounds.....	15
1-3. Provisional Minimal Risk Levels (MRLs) for PFOA.....	19
1-4. Provisional Minimal Risk Levels (MRLs) for PFOS	19
1-5. Provisional Minimal Risk Levels (MRLs) for PFHxS	20
1-6. Provisional Minimal Risk Levels (MRLs) for PFNA.....	20
2-1. Levels of Significant Exposure to PFOA – Inhalation	30
2-2. Levels of Significant Exposure to Other Perfluoroalkyls – Inhalation.....	33
2-3. Levels of Significant Exposure to PFOA – Oral	35
2-4. Levels of Significant Exposure to PFOS – Oral	62
2-5. Levels of Significant Exposure to Other Perfluoroalkyls – Oral.....	85
2-6. Levels of Significant Exposure to PFOA – Dermal	104
2-7. Summary of Childhood Growth in Humans	110
2-8. Summary of Cardiovascular Outcomes in Humans.....	125
2-9. Summary of Skeletal Outcomes in Humans	142
2-10. Summary of Liver Disease in Humans	148
2-11. Summary of Alterations in Serum Hepatic Enzymes and Bilirubin Levels in Humans	150
2-12. Summary of Serum Lipid Outcomes in Humans.....	156
2-13. Summary of Renal Outcomes in Humans.....	203
2-14. Summary of Uric Acid Outcomes in Humans	206
2-15. Summary of Thyroid Outcomes in Humans	223
2-16. Summary of Immunological Outcomes in Humans	245
2-17. Summary of Neurological Outcomes in Humans	294
2-18. Summary of Alterations in Reproductive Hormone Levels in Humans	301
2-19. Summary of Male Reproductive Outcomes in Humans	308

2-20. Summary of Female Reproductive Outcomes in Humans.....	313
2-21. Summary of Fertility Outcomes in Humans.....	318
2-22. Summary of Pregnancy Outcomes in Humans.....	341
2-23. Summary of Birth Outcomes in Humans.....	344
2-24. Summary of Neurodevelopmental Outcomes in Humans.....	360
2-25. Summary of Effects on the Development of the Reproductive System in Humans.....	371
2-26. Summary of Outcomes Related to Diabetes in Humans.....	407
2-27. Summary of Cancer Outcomes in Humans.....	419
2-28. Transactivation of Human and Mouse PPAR α in Transfected Cos-1 Cells Exposed to Perfluoroalkyl Compounds (In Order of Decreasing C _{20max} in the Mouse).....	436
2-29. Gene Expression Changes Induced by Perfluoroalkyl Compounds.....	439
2-30. Hepatic Effects of Perfluoroalkyl Compounds in Wild-Type and PPAR α -Null Mice Exposed Orally.....	442
3-1. Tissue Distribution and Excretion of ¹⁴ C-Radioactivity from Both Sexes of Rats, Mice, Hamsters, and Rabbits Dosed with ¹⁴ C-Labeled APFO.....	461
3-2. Serum (or Plasma) Concentrations in Matched Human Maternal-Infant Pairs.....	463
3-3. Matched Serum (or Plasma) and Breast Milk Concentrations in Humans.....	467
3-4. Excretory Clearance of PFOA and PFOS in Humans.....	471
3-5. Summary Elimination Half-Lives for Perfluoroalkyls Estimated in Humans and Experimental Animals.....	473
3-6. Summary Systemic Clearance for Perfluoroalkyls Estimated in Experimental Animals.....	481
3-7. Estimated and Assumed Pharmacokinetic Parameters for the Modified Andersen et al. (2006) Model for PFOA and PFOS.....	508
4-1. Chemical Identity of Perfluoroalkyls.....	522
4-2. Physical and Chemical Properties of Perfluoroalkyls.....	527
5-1. Content (ppm) and Percent Reduction of PFOA, PFOA Homologues, or PFOA Precursors in Products from 2006 and 2013 U.S. Operations of Fluoropolymer/Fluorotelomer Companies.....	541
5-2. U.S. Production Volume Ranges for Perfluoroalkyls (1986–2002) Reported under the EPA Inventory Update Rule.....	545

5-3. Reported Emissions of PFOA, PFOA Homologues, or PFOA Precursors in Products from the 2006 and 2013 U.S. Operations of Fluoropolymer/Fluorotelomer Companies.....	547
5-4. Global Historical PFCA Production and Emissions Estimates from 1951 to 2004.....	550
5-5. Biological Monitoring of PFOA and PFOS in the Arctic.....	556
5-6. Lowest Limit of Detection Based on Standards	562
5-7. Summary of Environmental Levels of Perfluoroalkyls	562
5-8. Perfluoroalkyls Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	563
5-9. Concentrations of Perfluoroalkyl in Outdoor Air.....	565
5-10. Concentrations of Perfluoroalkyl in Indoor Air.....	568
5-11. Concentration (ng/g) of Perfluoroalkyls in 39 Dust Samples.....	570
5-12. Concentrations of PFOA and PFOS in Surface Water (ng/L).....	572
5-13. Concentrations of Other Perfluoroalkyls in Surface Water	574
5-14. Concentrations of Perfluoroalkyls in Surface Water and Groundwater at Fluorochemical Industrial Facilities	576
5-15. Concentrations of PFOA and PFOS in Ocean Water	578
5-16. Concentrations of Perfluoroalkyls in Soil and Sediment at Fluorochemical Industrial Facilities	583
5-17. Summary of Perfluoroalkyl Compounds Detected in Soil, Sediment, Surface Water, and Groundwater at 10 Military Installations.....	586
5-18. Detections of PFOA in 31 U.S. Food Items	588
5-19. Detections of Perfluoroalkyls in Fish from U.S. Lakes and Rivers.....	589
5-20. Fluorotelomer Alcohols Detected in Microwaveable Popcorn Bags Produced in China and the United States.....	594
5-21. Concentrations of PFOA and PFOS in Human Serum Collected in the United States	597
5-22. Concentrations of Other Perfluoroalkyls in Human Serum Collected in the United States	600
5-23. Concentrations of PFOA, PFOS, and PFHxS in Human Serum for Occupationally Exposed Individuals	608
5-24. Percent Detection and Levels of PFOA and PFOS in Children’s Serum, Umbilical Cord Blood, and Breast Milk.....	611

5-25. Percent Detection and Levels of Other Perfluoroalkyls in Children’s Serum, Umbilical Cord Blood, and Breast Milk.....	616
5-26. Blood Serum Levels for 69,030 Current and Former Residents of Six Water Districts in the Mid-Ohio Valley (2005–2006).....	625
6-1. Ongoing Studies on Perfluoroalkyls.....	642
7-1. Regulations and Guidelines Applicable to Perfluoroalkyls.....	644
7-2. Select State Drinking Water and Daily Intake Levels for Perfluoroalkyls.....	646